Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293657 · ClinicalTrials.gov registry record · Phase 2
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
A Phase 2 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00293657: Completed Phase 2 study, sponsored by POZEN.
NCT00293657 is a Phase 2 study that has completed, run by POZEN. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00293657, a Phase 2 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of migraine. Two-thirds of patients in this study will receive a single dose of intravenous lornoxicam (8mg or 16 mg) and one-third of patients will receive a single dose of an intravenous placebo.
Interventions
- DRUG Placebo
- DRUG Lornoxicam 8 mg
- DRUG Lornoxicam 16 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00293657 record still lists
NCT00293657 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00293657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00293657 about?
NCT00293657 is a clinical study titled "Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.". To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of migraine. Two-thirds of patients in this study will receive a single dose of i...
What is the current status of trial NCT00293657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-12. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00293657?
The interventions under investigation include: Placebo (DRUG), Lornoxicam 8 mg (DRUG), Lornoxicam 16 mg (DRUG).
Who is sponsoring clinical trial NCT00293657?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00293657's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia